2021 Saul Hertz, MD Award Winner: Eric Krenning, MD, PhD, FRCP

The Saul Hertz, MD Award is a lifetime achievement award, recognizing individuals who have made outstanding contributions to radionuclide therapy.  

In 2021, the award was presented to Eric Krenning, MD, PhD, FRCP. Dr Krenning completed his MD in 1972, is board certified both in Internal Medicine (since 1978) and Nuclear Medicine (since 2000), achieved a PhD by thesis at the Erasmus University of Rotterdam in 1983. He had a position as staff-physician in the Department of Internal Medicine and Endocrinology (1978 - 2012) and head of Department of Nuclear Medicine at the Erasmus MC, Rotterdam (1985 - 2012); is Professor of Nuclear Medicine (since 1990) and was made a Fellow of the Royal College of Physicians, London, UK, in 1999. He is the founder and director of the research-facility Cyclotron Rotterdam BV, situated on the campus of Erasmus MC, Rotterdam, (2012 - present).

Dr Krenning has fulfilled educational responsibilities at the Erasmus MC, lecturing in Internal Medicine, Nuclear Medicine and Endocrinology throughout his career.  As a member of medical advisory boards of Dutch patient associations for thyroid disorders, he was actively involved in patient education (1991 - 2012).

He is an honorary member of the Royal College of Physicians, London, UK (1999), the European Association of Nuclear Medicine (EANM, 2012) and the European Neuro-Endocrine Tumor Society (ENETS, 2014).

Dr Krenning started his medical research in 1975. His main interests include thyroidology and nuclear endocrinology with radiolabelled peptides with their introduction to peptide receptor imaging and therapy, initially focusing on patients with neuroendocrine tumors (NET): “from bench to bed”. Dr Krenning was instrumental in the conception, the development and the first approvals of somatostatin analog based radiopharmaceuticals, namely OctreoScan (Peptide Receptor Scintigraphy/Imaging, by FDA in 1994 and EMEA in 1995) and Lutathera (Peptide Receptor Radionuclide Therapy (PRRT), by EMA in 2017 and FDA in 2018) for NET and the lysine/arginine product Lysakare (by EMA in 2019) for kidney protection during PRRT with somatostatin analogs (reference: Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. Rachel Levine and Eric P. Krenning. J Nucl Med 2017; 58:3S–9S; DOI: 10.2967/jnumed.116.1865).

Dr Krenning (co-)authored more than 500 peer-reviewed articles since 1975, more than 150 chapters and proceedings in the field of thyroidology and peptide receptor scintigraphy and radionuclide therapy. In these fields he also received awards and invitations to give honourable lectures.

In June 2021, his scientific H-index is 101 (“Web of Science”).

Eric Krenning, MD, PhD, FRCP